Gyre Therapeutics

Recent news

• Rating change
  H.C. Wainwright Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $18
  Market Newswire · 2025/8/26
• Rating change
  LifeSci Capital Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $22
  Market Newswire · 2025/6/19
• Company notice
  GNI Group: Gyre Therapeutics to Participate in U.S. Healthcare Conferences
  JPX · 2026/9/4
• Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate
  Benzinga · 2026/5/7
• Company notice
  GNI Group: Notice Regarding the Release of Corporate Presentation Materials by Consolidated Subsidiary Gyre Therapeutics, Inc.
  JPX · 2026/6/3
• Company notice
  GNI Group: Regarding Gyre Therapeutics' Participation in the U.S. Healthcare Conference
  JPX · 2026/9/4
• Rating change
  Wedbush Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $27
  Market Newswire · 2025/7/15
• Rating change
  Jefferies Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $16
  Market Newswire · 2025/10/10
• Rating change
  H.C. Wainwright Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $25
  Market Newswire · 2025/8/11
• Gyre Therapeutics Q4 Adj. EPS $0.05 Misses $0.06 Estimate, Sales $37.195M Beat $36.303M Estimate
  Benzinga · 2026/3/12
• H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)
  TipRanks · 2026/8/7
• H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18
  Market Newswire · 2026/10/5
• Company notice
  GNI Group: Notice Regarding the Release of Corporate Presentation Materials by Consolidated Subsidiary Gyre Therapeutics, Inc.
  JPX · 2026/8/27
• Rating change
  H.C. Wainwright Initiates a Buy Rating on Gyre Therapeutics (GYRE)
  TipRanks · 2025/8/11
• Rating change
  TR | OpenAI - 4o Maintains Gyre Therapeutics(GYRE.US) With Hold Rating, Raises Target Price to $8.5
  Market Newswire · 2025/8/24
• Rating change
  Noble Financial Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $20
  Market Newswire · 2025/3/12
• Rating change
  Stifel Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $28
  Market Newswire · 2025/6/25
• Company notice
  Gyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Epstein David M.
  SEC · 2026/7/1
• Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20
  Market Newswire · 2026/8/10

Headlines are aggregated automatically and are not independently verified or edited by our team.